ArticleFocus (American Psychiatric Publishing)2025
Anhedonia as a Core Symptom of Depression and a Construct for Biological Research.
Article in Focus (American Psychiatric Publishing), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bridging Neurobiology, Heterogeneity, and Comorbidity in Mood Disorders.Brain sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anhedonia is a key psychiatric symptom that has seen significant advances in its understanding in both clinical practice and research over the past few decades. Once considered primarily a feature of depression, recent studies have shown that anhedonia is also a core element of other psychiatric disorders and contributes to considerable morbidity, mortality, and suicidality. Emerging models of psychopathology and illness emphasize the transdiagnostic relevance of anhedonia. At the same time, neuroimaging research has provided deeper insights into its underlying pathophysiology, and several assessment scales with strong psychometric properties have been developed. Various treatment strategies-including psychopharmacology, neuromodulation, and psychotherapy-have demonstrated varying degrees of effectiveness. This review discusses the evolving understanding of anhedonia, its significance as both a symptom and a diagnostic marker, its prevalence, and its pathophysiological underpinnings. Additionally, the authors provide an overview of key assessment tools and explore the range of treatment approaches studied to date.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.